146 related articles for article (PubMed ID: 24905400)
1. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy.
Alqawlaq S; Sivak JM; Huzil JT; Ivanova MV; Flanagan JG; Beazely MA; Foldvari M
Nanomedicine; 2014 Nov; 10(8):1637-47. PubMed ID: 24905400
[TBL] [Abstract][Full Text] [Related]
2. A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: an implication for cell membrane nanoporation.
Gharagozloo M; Rafiee A; Chen DW; Foldvari M
J Nanobiotechnology; 2015 Sep; 13():62. PubMed ID: 26415935
[TBL] [Abstract][Full Text] [Related]
3. Multipotent stem cell-derived retinal ganglion cells in 3D culture as tools for neurotrophic factor gene delivery system development.
Chen DW; Narsineni L; Foldvari M
Nanomedicine; 2019 Oct; 21():102045. PubMed ID: 31255791
[TBL] [Abstract][Full Text] [Related]
4. Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma.
Alqawlaq S; Huzil JT; Ivanova MV; Foldvari M
Nanomedicine (Lond); 2012 Jul; 7(7):1067-83. PubMed ID: 22846092
[TBL] [Abstract][Full Text] [Related]
5. BDNF gene delivery to the retina by cell adhesion peptide-conjugated gemini nanoplexes in vivo.
Narsineni L; Chen DW; Foldvari M
J Control Release; 2023 Jul; 359():244-256. PubMed ID: 37257566
[TBL] [Abstract][Full Text] [Related]
6. A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies.
Rathod LV; Kapadia R; Sawant KK
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():529-540. PubMed ID: 27987741
[TBL] [Abstract][Full Text] [Related]
7. Rescue of retinal function by BDNF in a mouse model of glaucoma.
Domenici L; Origlia N; Falsini B; Cerri E; Barloscio D; Fabiani C; Sansò M; Giovannini L
PLoS One; 2014; 9(12):e115579. PubMed ID: 25536045
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer with liposomes to the intraocular tissues by different routes of administration.
Masuda I; Matsuo T; Yasuda T; Matsuo N
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1914-20. PubMed ID: 8759362
[TBL] [Abstract][Full Text] [Related]
9. Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles.
Apaolaza PS; Del Pozo-Rodríguez A; Solinís MA; Rodríguez JM; Friedrich U; Torrecilla J; Weber BH; Rodríguez-Gascón A
Biomaterials; 2016 Jun; 90():40-9. PubMed ID: 26986855
[TBL] [Abstract][Full Text] [Related]
10. Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.
Feng L; Li SK; Liu H; Liu CY; LaSance K; Haque F; Shu D; Guo P
Pharm Res; 2014 Apr; 31(4):1046-58. PubMed ID: 24297069
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
[TBL] [Abstract][Full Text] [Related]
12. An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration.
Zhao L; Chen G; Li J; Fu Y; Mavlyutov TA; Yao A; Nickells RW; Gong S; Guo LW
J Control Release; 2017 Feb; 247():153-166. PubMed ID: 28063892
[TBL] [Abstract][Full Text] [Related]
13. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles.
Farjo R; Skaggs J; Quiambao AB; Cooper MJ; Naash MI
PLoS One; 2006 Dec; 1(1):e38. PubMed ID: 17183666
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives.
Naik S; Shreya AB; Raychaudhuri R; Pandey A; Lewis SA; Hazarika M; Bhandary SV; Rao BSS; Mutalik S
Life Sci; 2021 Jan; 264():118712. PubMed ID: 33159955
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable Nanoparticles Based on Pseudo-Proteins Show Promise as Carriers for Ophthalmic Drug Delivery.
Zhang W; Kantaria T; Zhang Y; Kantaria T; Kobauri S; Tugushi D; Brücher V; Katsarava R; Eter N; Heiduschka P
J Ocul Pharmacol Ther; 2020; 36(6):421-432. PubMed ID: 32639222
[No Abstract] [Full Text] [Related]
16. Inner retinal injury in experimental glaucoma is prevented upon AAV mediated Shp2 silencing in a caveolin dependent manner.
Abbasi M; Gupta VK; Chitranshi N; Gupta V; Ranjbaran R; Rajput R; Pushpitha K; Kb D; You Y; Salekdeh GH; Parton RG; Mirzaei M; Graham SL
Theranostics; 2021; 11(13):6154-6172. PubMed ID: 33995651
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cellular uptake and intracellular trafficking as determining factors of gene expression for amino acid-substituted gemini surfactant-based DNA nanoparticles.
Singh J; Michel D; Chitanda JM; Verrall RE; Badea I
J Nanobiotechnology; 2012 Feb; 10():7. PubMed ID: 22296763
[TBL] [Abstract][Full Text] [Related]
18. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
[TBL] [Abstract][Full Text] [Related]
19. Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells.
Langouet-Astrie CJ; Yang Z; Polisetti SM; Welsbie DS; Hauswirth WW; Zack DJ; Merbs SL; Enke RA
Exp Eye Res; 2016 Oct; 151():61-7. PubMed ID: 27481653
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of Cy5-labeled Thiolated and Methylated Chitosan-Carboxymethyl Dextran Nanoparticles in an Animal Model of Retinoblastoma.
Delrish E; Ghassemi F; Jabbarvand M; Lashay A; Atyabi F; Soleimani M; Dinarvand R
J Ophthalmic Vis Res; 2022; 17(1):58-68. PubMed ID: 35194497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
